RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. 2021

Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

The NLRP3 inflammasome plays a crucial role in innate immune-mediated inflammation and contributes to the pathogenesis of multiple autoinflammatory, metabolic and neurodegenerative diseases, but medications targeting the NLRP3 inflammasome are not available for clinical use. RRx-001 is a well-tolerated anticancer agent currently being investigated in phase III clinical trials, but its effects on inflammatory diseases are not known. Here, we show that RRx-001 is a highly selective and potent NLRP3 inhibitor that has strong beneficial effects on NLRP3-driven inflammatory diseases. RRx-001 inhibits the activation of the canonical, noncanonical, and alternative NLRP3 inflammasomes but not the AIM2, NLRC4 or Pyrin inflammasomes. Mechanistically, RRx-001 covalently binds to cysteine 409 of NLRP3 via its bromoacetyl group and therefore blocks the NLRP3-NEK7 interaction, which is critical for the assembly and activation of the NLRP3 inflammasome. More importantly, RRx-001 treatment attenuates the symptoms of lipopolysaccharide (LPS)-induced systemic inflammation, dextran sulfate sodium (DSS)-induced colitis and experimental autoimmune encephalomyelitis (EAE) in mice. Thus, our study identifies RRx-001 as a new potential therapeutic agent for NLRP3-driven diseases.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009574 Nitro Compounds Compounds having the nitro group, -NO2, attached to carbon. When attached to nitrogen they are nitramines and attached to oxygen they are NITRATES. Nitrated Compounds
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D000071199 NLR Family, Pyrin Domain-Containing 3 Protein An NLR protein that contains an N-terminal PYRIN DOMAIN and ATP-binding site and 9 C-terminal LEUCINE-rich repeats; it is expressed primarily by MACROPHAGES. It is a core component of the INFLAMMASOME and directs its assembly in response to pathogen infection and damage-associated stimuli. Mutations in the NLRP3 gene are associated with FAMILIAL COLD AUTOINFLAMMATORY SYNDROME. Cold Autoinflammatory Syndrome 1 Protein,NACHT, LRR and PYD Domains-Containing Protein 3,NLRP3 Protein,NACHT, LRR and PYD Domains Containing Protein 3,NLR Family, Pyrin Domain Containing 3 Protein
D000072379 NIMA-Related Kinases A highly conserved family of protein serine-threonine kinases that regulate the CELL CYCLE; MITOSIS; and the response to DNA DAMAGE. They are also involved in the assembly and function of microtubule-based structures such as CILIA and CENTRIOLES. NEK Family Kinase,NEK Kinase,NIMA Family Kinase,NIMA-Related Kinase,Never-in-Mitosis A Kinase,NEK Family Kinases,NEK Kinases,NIMA Family Kinases,NIMA Protein Kinase,NIMA-Related Protein Kinase,Never-in-Mitosis A Kinases,A Kinase, Never-in-Mitosis,Family Kinase, NEK,Family Kinase, NIMA,Kinase, NEK,Kinase, NEK Family,Kinase, NIMA Family,Kinase, NIMA-Related,Kinase, Never-in-Mitosis A,Kinases, NEK,Kinases, NEK Family,Kinases, NIMA Family,Kinases, NIMA-Related,Kinases, Never-in-Mitosis A,NIMA Related Kinase,NIMA Related Kinases,NIMA Related Protein Kinase,Never in Mitosis A Kinase,Never in Mitosis A Kinases

Related Publications

Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
January 2023, Frontiers in oncology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
April 2023, Drugs,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
January 2022, Frontiers in pharmacology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
April 2024, International immunopharmacology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
June 2016, Investigational new drugs,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
January 2024, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
June 2023, British journal of pharmacology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
May 2018, Oncotarget,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
October 2020, International immunopharmacology,
Yun Chen, and Hongbin He, and Bolong Lin, and Yun Chen, and Xianming Deng, and Wei Jiang, and Rongbin Zhou
January 2022, American journal of cancer research,
Copied contents to your clipboard!